https://www.selleckchem.com/pr....oducts/zidesamtinib.
IR of serious TEAEs for all patients was 7.5 (6.4-8.8); 6.7 (5.2-8.3) and 8.7 (6.9-10.8) for CZP 200 mg and 400 mg Q2W, respectively. 3.2% patients reported serious infections (2.2% within each of the CZP 200 and 400 mg Q2W groups). Overall, there was 1 case of active tuberculosis, 16 malignancies in 14 patients and 7 deaths (2 considered treatment-related). Cumulative IR of TEAEs did not increase over time. Conclusions No new safety signals were identified compared to previously reported data. Risk did not increase with longer or
Beğen
Yorum Yap
Paylaş
